We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Precision BioSciences (DTIL) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Precision BioSciences (DTIL - Free Report) closed the most recent trading day at $4.28, moving -1.83% from the previous trading session. This change lagged the S&P 500's daily gain of 2.24%. At the same time, the Dow added 2.51%, and the tech-heavy Nasdaq lost 0.17%.
Heading into today, shares of the genome editing company had gained 2.59% over the past month, outpacing the Medical sector's loss of 1% and the S&P 500's loss of 2.58% in that time.
Precision BioSciences will be looking to display strength as it nears its next earnings release. In that report, analysts expect Precision BioSciences to post earnings of -$0.50 per share. This would mark a year-over-year decline of 13.64%. Meanwhile, our latest consensus estimate is calling for revenue of $8.24 million, down 6.86% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for Precision BioSciences. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Precision BioSciences is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 150, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Precision BioSciences (DTIL) Stock Sinks As Market Gains: What You Should Know
Precision BioSciences (DTIL - Free Report) closed the most recent trading day at $4.28, moving -1.83% from the previous trading session. This change lagged the S&P 500's daily gain of 2.24%. At the same time, the Dow added 2.51%, and the tech-heavy Nasdaq lost 0.17%.
Heading into today, shares of the genome editing company had gained 2.59% over the past month, outpacing the Medical sector's loss of 1% and the S&P 500's loss of 2.58% in that time.
Precision BioSciences will be looking to display strength as it nears its next earnings release. In that report, analysts expect Precision BioSciences to post earnings of -$0.50 per share. This would mark a year-over-year decline of 13.64%. Meanwhile, our latest consensus estimate is calling for revenue of $8.24 million, down 6.86% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for Precision BioSciences. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Precision BioSciences is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 150, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.